Please assess the completion status of the following clinical trial:

Trial Title: Vitamin B12a Vasoplegic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient for whom we are able to obtain consent ahead of their procedure~* Patients presenting for a procedure in which cardiopulmonary bypass will be required~* Considered high risk for vasoplegic syndrome~* Has no contraindications to arterial line or PA catheter placement~* Develops high-dose vasopressors for 30 min or longer and refractory hypotension consistent with vasoplegic syndrome within 24 hours of coming off cardiopulmonary bypass.~Exclusion Criteria:~* Age\<18 years~* Known pregnancy or patients without a documented pregnancy test if not menopausal.~* Known prior anaphylactic or allergic reaction to B12a~* CKD stage 4 or worse~* ECMO (extracorporeal membrane oxygenation) prior to study consent.~* Patients currently on cardiopulmonary bypass

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B12a (Type: EXPERIMENTAL): Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).